Australia-based startup AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, has entered into a Collaboration and Exclusive Licensing Agreement with Canadian startup 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need, reflecting AdvanCell’s strategy to build a durable pipeline of differentiated targeted alpha therapies addressing large oncology markets.
The collaboration brings together 48Hour Discovery’s peptide discovery platform and AdvanCell’s 212Pb expertise to rapidly construct and advance a peptide-based radiotherapeutic program. Leveraging AdvanCell’s scalable 212Pb platform, which integrates secure isotope supply and modular manufacturing with deep expertise in developing 212Pb radioligand therapies, the program is designed to enable a rapid, repeatable path into the clinic and support the expansion of AdvanCell’s targeted alpha therapy pipeline.
Under the terms of the agreement, AdvanCell has obtained exclusive worldwide rights for development and commercialisation.
This Collaboration and Exclusive Licensing Agreement expands the company’s existing portfolio of targeted alpha therapies, led by ADVC001, a first-in-class 212Pb-PSMA radioligand therapy.
